[The modified program NHL-BFM-90 in the treatment of patients with diffuse large B-cell lymphosarcoma].
OBJECTIVE
To investigate efficacy of the modified protocol NHL-BFM-90 in patients with diffuse large B-cell lymphosarcoma (DLBCLS).


METHODS
A total of 13 DLBCLS patients with stage II-IV of the disease with affection of lymph nodes at the disease onset (nodal lesion) and stage II with tumor size more than 10 cm (bulky disease) received first-line treatment according to the modified program NHL-BFM-90 from 2002 to 2005. The diagnosis was made by WHO criteria.


RESULTS
A complete remission was achieved in 76.9% patients. Resistance to therapy was observed in the patients with bone marrow affection. The 2.5-year overall survival was 74%, 2-year event-free survival was 75% (the events were recurrence and resistance). Follow-up continued from 5 to 47 months.


CONCLUSIONS
The efficacy of the modified protocol NHL-BFM-90 in DLBCLS patients with stage III-IV of the "nodal" disease and stage II of the "bulky" disease was high.
Magomedova
A U
AU
Kravchenko
S K
SK
Kremenetskaia
A M
AM
Zvonkov
E E
EE
Bariakh
E A
EA
Margolin
O V
OV
Kaplanskaia
I B
IB
Vorob'ev
I A
IA
Samoĭlova
R S
RS
Obukhova
T N
TN
Moiseeva
T N
TN
Zybunova
E E
EE
Gemdzhian
E G
EG
Vorob'ev
A I
AI
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D016393:Lymphoma, B-Cell / Q000150:complications* / Q000188:drug therapy* / Q000401:mortality; D016403:Lymphoma, Large B-Cell, Diffuse / Q000150:complications* / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D015996:Survival Rate